Yes, I’m glad they are spending <5% of the cash burn needed to advance these other areas while waiting on combo safety data. I wonder if the same people complaining that they should focus on one area will be the same people to post concerns that others are advancing these other areas also. It is great that leronlimab has a 10 year head start in hiv with all the connections and IP that RP brings in the new cancer area and about to get its first approval.